Opinion

Video

NATALEE and monarchE: Clinical Data Review and Insights Into Treating High-Risk HR+/HER2_ Early-Stage Breast Cancer

Panelists discuss the recent data from the NATALEE and monarchE studies, focusing on adjuvant CDK4/6 inhibitor selection for high-risk HR-positive/HER2-negative (HR+/HER2–) early breast cancer patients, and explore how to interpret the different efficacy signals, particularly the early curve separation observed in monarchE versus NATALEE.

Video Player is loading.
Current Time 0:00
Duration 4:37
Loaded: 3.55%
Stream Type LIVE
Remaining Time 4:37
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Video content above is prompted by the following:

  • Based on the monarchE and NATALEE trials, how do you approach adjuvant CDK4/6 inhibitor selection for patients with high-risk HR+/HER2– early breast cancer?
  • How do you weigh the different efficacy signals between the trials, particularly the early separation of curves in monarchE versus NATALEE?
Related Content